Farzana Kapadia

Farzana Kapadia

Auto-generated profile, based on publicly available information

Farzana Kapadia

Farzana Kapadia is the deputy editor of AJPH and professor of epidemiology at the School of Global Public Health, New York University, New York

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2015 in AIDS Education and Prevention
Verified
Journal Article
Closed access
RPRafael E. Pérez-Figueroa
Rafael E. Pérez-Figueroa
FKFarzana Kapadia
Farzana Kapadia
SBStaci C. Barton
Staci C. Barton
JEJessica A. Eddy
Jessica A. Eddy
PHPerry N. Halkitis
Perry N. Halkitis

1 September 2007 in AIDS
Verified
Journal Article
Closed access
RGRichard S Garfein
Richard S Garfein
EGElizabeth T Golub
Elizabeth T Golub
AGAlan E Greenberg
Alan E Greenberg
HHHolly Hagan
Holly Hagan
DHDebra L Hanson
Debra L Hanson
HTHanne Thiede
Hanne Thiede
To evaluate whether a behavioral intervention, which taught peer education skills, could reduce injection and sexual risk behaviors associated with primary HIV and hepatitis C virus infection (HCV) among young injection drug users (IDU). We conducted a randomized controlled trial involving HIV and HCV antibody-negative IDU, aged 15-30 years, recruited in five United States cities. A six-session, small-group, cognitive behavioral, skills-building intervention in which participants were taught peer education skills (n = 431) was compared with a time-equivalent attention control (n = 423). Baseline visits included interviews for sociodemographic, psychosocial, and behavioral factors during the previous 3 months; HIV and HCV antibody testing; and pre/posttest counselling. Procedures were repeated 3 and 6 months postintervention. The intervention produced a 29% greater decline in overall injection risk 6 months postintervention relative to the control [proportional odds ratio 0.71; 95% confidence limit (CL) 0.52, 0.97], and a 76% decrease compared with baseline. Decreases were also observed for sexual risk behaviors, but they did not differ by trial arm. Overall HCV infection incidence (18.4/100 person-years) did not differ significantly across trial arms (relative risk 1.15; 95% CL 0.72, 1.82). No HIV seroconversions were observed. Interventions providing information, enhancing risk-reduction skills, and motivating behavior change through peer education training can reduce injection risk behaviors, although risk elimination might be necessary to prevent HCV transmission.

1 November 2006 in Public Health Reports®
Verified
Journal Article
Closed access
HHHolly Hagan
Holly Hagan
JCJennifer Campbell
Jennifer Campbell
HTHanne Thiede
Hanne Thiede
SSSteffanie Strathdee
Steffanie Strathdee
LOLawrence Ouellet
Lawrence Ouellet
RGRichard S. Garfein
Richard S. Garfein
Objective.: This study was conducted to assess the accuracy of self-reported hepatitis C virus (HCV) antibody (anti-HCV) serostatus in injection drug users (IDUs), and examine whether self-reported anti-HCV serostatus was associated with recent injection risk behavior. Methods.: In five U.S. cities (Baltimore, Chicago, Los Angeles, New York, and Seattle), 3,004 IDUs from 15 to 30 years old were recruited for a baseline interview to determine eligibility for a randomized controlled trial of a behavioral intervention. HIV and HCV antibody testing were performed, and subject data (e.g., demographics, drug and sexual risk behavior, and history of HIV and HCV testing) were collected via audio computer-administered self-interview. Risk behavior during the previous three months was compared to self-reported anti-HCV serostatus. Results.: Anti-HCV prevalence in this sample of young IDUs was 34.1%. Seventy-two percent of anti-HCV-positive and 46% of anti-HCV-negative IDUs in this sample were not aware of their HCV serostatus. Drug treatment or needle exchange use was associated with increased awareness of HCV serostatus. Anti-HCV-negative IDUs who knew their serostatus were less likely than those unaware of their status to inject with a syringe used by another IDU or to share cottons to filter drug solutions. Knowledge of one's positive anti-HCV status was not associated with safer injection practices. Conclusions.: Few anti-HCV-positive IDUs in this study were aware of their serostatus. Expanded availability of HCV screening with high quality counseling is clearly needed for this population to promote the health of chronically HCV-infected IDUs and to decrease risk among injectors susceptible to acquiring or transmitting HCV.

1 October 2005 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
FKFarzana Kapadia
Farzana Kapadia
DVDavid Vlahov
David Vlahov
RDRobert M. Donahoe
Robert M. Donahoe
GFGerald Friedland
Gerald Friedland
From the onset of the HIV/AIDS epidemic, the use of licit and illicit drugs has been investigated for its potential impact on HIV disease progression

1 June 2007 in Drug and Alcohol Dependence
Verified
Journal Article
Closed access
JCJudith A. Cook
Judith A. Cook
DGDennis D. Grey
Dennis D. Grey
JBJane K. Burke-Miller
Jane K. Burke-Miller
MCMardge H. Cohen
Mardge H. Cohen
DVDavid Vlahov
David Vlahov
ALAlexandra M. Levine
Alexandra M. Levine

15 April 2005 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
Steffanie StrathdeeSteffanie Strathdee
Steffanie Strathdee
MLM. Latka
M. Latka
JCJ. Campbell
J. Campbell
POP. T. O’driscoll
P. T. O’driscoll
EGE. T. Golub
E. T. Golub
SPStudy to Reduce Intravenous Exposures Project
Study to Reduce Intravenous Exposures Project
Objective. We sought to identify factors associated with interest in receiving therapy for hepatitis C virus (HCV) infection among HCV-infected injec